This year’s American Society of Hematology (ASH) meeting, which is taking place in Atlanta, came to a close earlier today.  However, yesterday, the third day of the meeting, was packed with myeloma-related presentations.

Given the number of myeloma presentations made yesterday, The Beacon will summarize the four most important of yesterday’s oral presentation sessions as well as a number of the most important poster presentations in updates such as this one.  Summaries of the first three key oral presentation sessions were published yesterday and earlier today.  This update covers presentations from the …

This year’s American Society of Hematology (ASH) meeting con­tinues in Atlanta.  Yesterday was the third day of the meeting and the busiest day in terms of myeloma-related presentations.  It was packed full of both oral and poster presentations.

There were so many myeloma-related talks given yesterday that many of them were held simultaneously.  The Beacon will therefore summarize presentations from the four most important sessions in updates such as this one.

This update covers presentations from the second of the four key oral presentation sessions.  An update published yesterday covers presentations from …

Today is the third day of the American Society of Hematology (ASH) 2012 annual meeting in Atlanta, and it is packed full with multiple myeloma-related presentations. Presentations started early in the morning and will con­tinue through the afternoon.

Over the course of today, at least 11 different oral sessions, many of which are being held simultaneously, will include presentations about myeloma-related topics.  The Beacon will summarize presentations from the four most relevant sessions in updates such as this one.  This update, in particular, covers presentations from the first of those four oral …

This year’s American Society of Hematology (ASH) annual meeting, which is being held in Atlanta, began yesterday and goes through Tuesday.

Today’s myeloma-related presentations began this afternoon with three sessions of oral presentations.  Two of the sessions focused on results from clin­i­cal trials, most of which studied drugs that are still under devel­op­ment as poten­tial treat­ments for multiple myeloma.  The third session, which focused on the biology of myeloma, ran simultaneously with one of the sessions about clin­i­cal trial results.

This article will summarize the first oral session about multiple myeloma treat­ments, …

The National Comprehensive Cancer Network (NCCN) has updated its guide­lines for the treat­ment of multiple myeloma, and the new guidelines will be interpreted by many as a vote of confidence for Revlimid main­te­nance ther­apy.

The NCCN guidelines are followed closely by physicians and by many U.S. health insurance com­pa­nies, which frequently use them when making reim­burse­ment decisions about different cancer treat­ments.

The guidelines are comprised of recommendations based on the results of recent clinical trials and ongoing scientific research.  A panel of specialists within the myeloma field is responsible for updating the …

Physicians in the United States are able to prescribe Kyprolis for their patients now that the drug has been approved for the treat­ment of multiple myeloma.

The drug's widespread availability, however, raises the important question: For what types of myeloma patients are physicians likely to prescribe Kyprolis?

Last month, the U.S. Food and Drug Administration (FDA) approved Kyprolis (car­filz­o­mib) for the treat­ment of multiple myeloma patients meeting specific criteria. The patients must have received at least two prior ther­a­pies, including Velcade (bor­tez­o­mib) and an immuno­modu­la­tory agent, meaning either Revlimid (lena­lido­mide), …

Final results from a Phase 2 study show that Kyprolis can be an effective treat­ment for re­lapsed and refractory multiple myeloma patients, with nearly a quarter of these patients responding to treat­ment.

Dr. David Siegel, from the John Theurer Cancer Center and lead investigator of the study, said the results dem­onstrate that Kyprolis (car­filz­o­mib) has “excellent activity with low toxicity.”

Based on the results of this study, the U.S. Food and Drug Administration recently approved Kyprolis for use in re­lapsed and refractory multiple myeloma patients (see related Beacon news).

“Patients …